SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA

被引：0
|
作者：
Fanale, M. [1 ]
Advani, R. [2 ]
Bartlett, N. L. [3 ]
Davies, A. [4 ]
Illidge, T. [5 ]
Kennedy, D. A. [6 ]
Shustov, A. R. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Southampton Univ Hosp, Southampton, Hants, England
[5] Univ Manchester, Christie Hosp NHS, Manchester, Lancs, England
[6] Seattle Genet Inc, Clin Affairs, Bothell, WA USA
[7] Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：348 / 348
页数：1
相关论文
共 50 条
  • [31] Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin
    Sasapu, Appalanaidu
    Dunn, Andrew L. J.
    Gardner, Jerad
    Wong, Henry K.
    BMJ CASE REPORTS, 2021, 14 (07)
  • [32] Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update
    Advani, Ranjana H.
    Shustov, Andrei R.
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2011, 118 (21) : 204 - 204
  • [33] BRENTUXIMAB VEDOTIN: ITS ROLE IN THE TREATMENT OF ANAPLASTIC LARGE CELL AND HODGKIN'S LYMPHOMA
    Haddley, K.
    DRUGS OF TODAY, 2012, 48 (04) : 259 - 270
  • [34] Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
    Ansell, Stephen M.
    Connors, Joseph M.
    Park, Steven I.
    O'Meara, Megan M.
    Younes, Anas
    BLOOD, 2012, 120 (21)
  • [35] Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma
    Advani, Ranjana
    Pro, Barbara
    Kennedy, Dana
    Fanale, Michelle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB4 - AB4
  • [36] Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
    Forero-Torres, Andres
    Berryman, R. Brian
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Chen, Robert W.
    Fanale, Michelle A.
    Gopal, Ajay K.
    O'Connor, Owen A.
    Olshefski, Randal
    Smith, Scott E.
    Grove, Laurie E.
    Matous, Jeffrey
    BLOOD, 2011, 118 (21) : 1585 - 1586
  • [37] Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports
    Broccoli, Alessandro
    Derenzini, Enrico
    Pellegrini, Cinzia
    Narducci, Riccardo
    Stefani, Giulia
    Casadei, Beatrice
    Argnani, Lisa
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 493 - 495
  • [38] Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
    Donato, Eva M.
    Fernandez-Zarzoso, Miguel
    Antonio Hueso, Jose
    de la Rubia, Javier
    ONCOTARGETS AND THERAPY, 2018, 11 : 4583 - 4590
  • [39] Nivolumab Outperforms Brentuximab Vedotin in Newly Diagnosed Advanced Hodgkin Lymphoma
    O'Brien, Susan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 359 - 359
  • [40] Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
    Younes, Anas
    Connors, Joseph M.
    Park, Steven I.
    Hunder, Naomi N. H.
    Ansell, Stephen M.
    BLOOD, 2011, 118 (21) : 436 - 437
12345